Absolute Antibody was founded in 2012 with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats.
Though recombinant antibodies are standard in the pharmaceutical industry, these antibodies have not been as widely available for diagnostics or research. This is starting to change, however, due to the many advantages recombinant antibodies offer over traditional hybridoma-produced monoclonal antibodies. Absolute Antibody has been at the forefront of the movement to make recombinant antibodies more readily available to all. In 2015, we were recognized in a Nature paper on the need to standardize research antibodies, and in 2018, we co-authored a mAbs Journal paper further illustrating the importance of using recombinant antibodies. Over the years, we have grown rapidly as demand for recombinant antibodies increases.